Please use this identifier to cite or link to this item:
|Title:||The antihyperalgesic effect of cytidine-5 '-diphosphate-choline in neuropathic and inflammatory pain models|
|Authors:||Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı.|
Uludağ Üniversitesi/Veterinerlik Fakültesi/Farmakoloji ve Toksikoloji Anabilim Dalı
Uludağ Üniversitesi/Veterinerlik Fakültesi/Fizyoloji Anabilim Dalı.
Sonat, Füsun Ak
Gürün, Mine Sibel
Neurosciences & neurology
Pharmacology & pharmacy
Gamma-aminobutyric acid receptors
Alpha 7 nicotinic receptors
|Publisher:||Lippincott Williams & Wilkins|
|Citation:||Bağdaş, D. vd. (2011). "The antihyperalgesic effect of cytidine-5 '-diphosphate-choline in neuropathic and inflammatory pain models". Behavioural Pharmacology, 22(5-6), 589-598.|
|Abstract:||This study was designed to test the effects of intracerebroventricularly (i.c.v.) administered CDP-choline (cytidine-5'-diphosphate-choline; citicoline) and its metabolites in rat models of inflammatory and neuropathic pain. The i.c.v. administration of CDP-choline (0.5, 1.0 and 2.0 mu mol) produced a dose and time-dependent reversal of mechanical hyperalgesia in both carrageenan-induced inflammatory and chronic constriction injury-induced neuropathic pain models in rats. The antihyperalgesic effect of CDP-choline was similar to that observed with an equimolar dose of choline (1 mu mol). The CDP-choline-induced antihyperalgesic effect was prevented by central administration of the neuronal high-affinity choline uptake inhibitor hemicholinium-3 (1 mu g), the nonselective nicotinic receptor antagonist mecamylamine (50 mu g), the alpha 7-selective nicotinic ACh receptor antagonist, alpha-bungarotoxin (2 mu g) and the gamma-aminobutyric acid B receptor antagonist CGP-35348 (20 mu g). In contrast, i.c.v. pretreatment with the nonselective opioid receptor antagonist naloxone (10 mu g) only prevented the CDP-choline-induced antihyperalgesic effect in the neuropathic pain model while the nonselective muscarinic receptor antagonist atropine (10 mu g) did not alter the antihyperalgesic effect in the two models. These results indicate that CDP-choline-elicited antihyperalgesic effect in different models of pain occurs through mechanisms that seem to involve an interaction with supraspinal alpha 7-selective nicotinic ACh receptors, and gamma-aminobutyric acid B receptors, whereas central opioid receptors have a role only in the neuropathic pain model. Behavioural Pharmacology 22:589-598 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.|
|Appears in Collections:||Scopus|
Web of Science
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.